These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 26754260)

  • 1. A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.
    Armstrong AJ; Halabi S; Healy P; Lee WR; Koontz BF; Moul JW; Mundy K; Creel P; Wood S; Davis K; Carducci MA; Stein M; Hobbs C; Reimer B; Nguyen M; Anand M; Bratt L; Kim S; Tran PT; George DJ;
    Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):100-6. PubMed ID: 26754260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.
    Zurita AJ; George DJ; Shore ND; Liu G; Wilding G; Hutson TE; Kozloff M; Mathew P; Harmon CS; Wang SL; Chen I; Chow Maneval E; Logothetis CJ
    Ann Oncol; 2012 Mar; 23(3):688-694. PubMed ID: 21821830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.
    Jang JW; Hwang WT; Guzzo TJ; Wein AJ; Haas NB; Both S; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1493-9. PubMed ID: 22401922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
    Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
    Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.
    McKay RR; Gray KP; Hayes JH; Bubley GJ; Rosenberg JE; Hussain A; Kantoff PW; Taplin ME
    Cancer; 2015 Aug; 121(15):2603-11. PubMed ID: 25903013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial.
    Bitting RL; Healy P; George DJ; Anand M; Kim S; Mayer T; Winters C; Riggan C; Rasmussen J; Wilder R; Stein M; Frizzell B; Harrison MR; Zhang T; Lee WR; Wu Y; Koontz BF; Armstrong AJ
    Eur Urol Oncol; 2021 Dec; 4(6):948-954. PubMed ID: 32063492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial.
    Zhang T; Howard L; Koontz BF; Tagawa ST; Nagar H; Bitting RL; Frizzell BA; Nordquist L; Rasmussen J; Riggan C; Reyes M; Davies C; Gray SR; Newman CR; Fernandez E; Ramalingam S; Harrison MR; George DJ; Wu Y; Armstrong AJ
    Eur Urol Oncol; 2024 Jul; ():. PubMed ID: 38971644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
    Stephenson AJ; Shariat SF; Zelefsky MJ; Kattan MW; Butler EB; Teh BS; Klein EA; Kupelian PA; Roehrborn CG; Pistenmaa DA; Pacholke HD; Liauw SL; Katz MS; Leibel SA; Scardino PT; Slawin KM
    JAMA; 2004 Mar; 291(11):1325-32. PubMed ID: 15026399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.
    Michaelson MD; Oudard S; Ou YC; Sengeløv L; Saad F; Houede N; Ostler P; Stenzl A; Daugaard G; Jones R; Laestadius F; Ullèn A; Bahl A; Castellano D; Gschwend J; Maurina T; Chow Maneval E; Wang SL; Lechuga MJ; Paolini J; Chen I
    J Clin Oncol; 2014 Jan; 32(2):76-82. PubMed ID: 24323035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypofractionated radiotherapy as salvage for rising prostate-specific antigen after radical prostatectomy.
    Lee LW; McBain CA; Swindell R; Wylie JP; Cowan RA; Logue JP
    Clin Oncol (R Coll Radiol); 2004 Dec; 16(8):517-22. PubMed ID: 15630843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment failure and clinical progression after salvage therapy in men with biochemical recurrence after radical prostatectomy: radiotherapy vs androgen deprivation.
    Song C; Kim YS; Hong JH; Kim CS; Ahn H
    BJU Int; 2010 Jul; 106(2):188-93. PubMed ID: 20002666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage radiation therapy following radical prostatectomy. A national Danish study.
    Ervandian M; Høyer M; Petersen SE; Sengeløv L; Hansen S; Holmberg M; Sveistrup J; Meidahl Petersen P; Borre M
    Acta Oncol; 2016 May; 55(5):598-603. PubMed ID: 26399602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer.
    Taguchi S; Fukuhara H; Azuma T; Suzuki M; Fujimura T; Nakagawa T; Ishikawa A; Kume H; Igawa Y; Homma Y
    BMC Urol; 2014 Oct; 14():81. PubMed ID: 25323845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: do outcomes differ?
    MacDonald OK; Schild SE; Vora S; Andrews PE; Ferrigni RG; Novicki DE; Swanson SK; Wong WW
    Urology; 2004 Oct; 64(4):760-4. PubMed ID: 15491716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
    Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer.
    Chen RC; Rosenman JG; Hoffman LG; Chiu WK; Wang AZ; Pruthi RS; Wallen EM; Crane JM; Kim WY; Rathmell WK; Godley PA; Whang YE
    BJU Int; 2012 Dec; 110(11 Pt B):E721-6. PubMed ID: 23016517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Select men benefit from androgen deprivation therapy delivered with salvage radiation therapy after prostatectomy.
    Holliday EB; Kuban DA; Levy LB; Bolukbasi Y; Master P; Choi S; Nguyen Q; McGuire SE; Mahmood U; Frank SJ; Hoffman KE
    Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):389-394. PubMed ID: 28462945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes after high-dose postprostatectomy salvage radiation treatment.
    Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):112-8. PubMed ID: 22300563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer.
    Ramey SJ; Agrawal S; Abramowitz MC; Moghanaki D; Pisansky TM; Efstathiou JA; Michalski JM; Spratt DE; Hearn JWD; Koontz BF; Liauw SL; Pollack A; Anscher MS; Den RB; Stephans KL; Zietman AL; Lee WR; Stephenson AJ; Tendulkar RD
    Eur Urol; 2018 Jul; 74(1):99-106. PubMed ID: 29128208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.